Wilma Uyterlinde

642 total citations
24 papers, 507 citations indexed

About

Wilma Uyterlinde is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiation. According to data from OpenAlex, Wilma Uyterlinde has authored 24 papers receiving a total of 507 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 6 papers in Radiation. Recurrent topics in Wilma Uyterlinde's work include Lung Cancer Diagnosis and Treatment (13 papers), Lung Cancer Treatments and Mutations (11 papers) and Advanced Radiotherapy Techniques (6 papers). Wilma Uyterlinde is often cited by papers focused on Lung Cancer Diagnosis and Treatment (13 papers), Lung Cancer Treatments and Mutations (11 papers) and Advanced Radiotherapy Techniques (6 papers). Wilma Uyterlinde collaborates with scholars based in Netherlands, United States and Belgium. Wilma Uyterlinde's co-authors include J. Belderbos, Michel M. van den Heuvel, Jan‐Jakob Sonke, Chun Chen, Josien de Bois, Margriet Kwint, Jasper Nijkamp, J. Knegjens, Edith Dieleman and Joachim G.J.V. Aerts and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

Wilma Uyterlinde

23 papers receiving 505 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wilma Uyterlinde Netherlands	10	350	177	175	137	74	24	507
Joanne Meng Canada	6	380 1.1×	176 1.0×	166 0.9×	176 1.3×	82 1.1×	7	508
Amanda Foster United States	15	542 1.5×	163 0.9×	249 1.4×	201 1.5×	54 0.7×	29	648
Qiuan Yang China	11	311 0.9×	82 0.5×	109 0.6×	178 1.3×	131 1.8×	23	445
Durmuş Etiz Türkiye	11	196 0.6×	119 0.7×	103 0.6×	56 0.4×	57 0.8×	30	350
W. Sause United States	4	928 2.7×	369 2.1×	219 1.3×	88 0.6×	109 1.5×	9	1.0k
Caitlin A. Schonewolf United States	10	209 0.6×	72 0.4×	96 0.5×	90 0.7×	74 1.0×	37	376
Takuhito Tada Japan	13	335 1.0×	197 1.1×	126 0.7×	197 1.4×	72 1.0×	37	507
Sara Falivene Italy	9	137 0.4×	315 1.8×	105 0.6×	60 0.4×	70 0.9×	27	521
Christina Armpilia Greece	9	160 0.5×	47 0.3×	145 0.8×	144 1.1×	38 0.5×	30	353

Countries citing papers authored by Wilma Uyterlinde

Since Specialization

Citations

This map shows the geographic impact of Wilma Uyterlinde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wilma Uyterlinde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wilma Uyterlinde more than expected).

Fields of papers citing papers by Wilma Uyterlinde

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wilma Uyterlinde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wilma Uyterlinde. The network helps show where Wilma Uyterlinde may publish in the future.

Co-authorship network of co-authors of Wilma Uyterlinde

This figure shows the co-authorship network connecting the top 25 collaborators of Wilma Uyterlinde. A scholar is included among the top collaborators of Wilma Uyterlinde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wilma Uyterlinde. Wilma Uyterlinde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Versluis, Judith M., Sofie Wilgenhof, A. Meerveld-Eggink, et al.. (2022). 854P Clinical features of acquired resistance (AR) in stage IV melanoma patients (pts) treated with immune checkpoint inhibition (ICI). Annals of Oncology. 33. S940–S940. 1 indexed citations

Kok, Iris C., Pim P. van de Donk, Danique Giesen, et al.. (2021). 89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer. Annals of Oncology. 33(1). 80–88. 71 indexed citations

Kos, Renate, Joris D. Veltman, Wilma Uyterlinde, et al.. (2020). Comparison of Myelotoxicity and Nephrotoxicity Between Daily Low-Dose Cisplatin With Concurrent Radiation and Cyclic High-Dose Cisplatin in Non-Small Cell Lung Cancer Patients. Frontiers in Pharmacology. 11. 975–975. 5 indexed citations

Sikorska, Karolina, Lindsay G. Grijpink-Ongering, Bart A. van de Wiel, et al.. (2018). Phase II study comparing pembrolizumab (PEM) with intermittent/short‐term dual MAPK pathway inhibition plus PEM in patients harboring the BRAFV600 mutation (IMPemBra). Annals of Oncology. 29. viii736–viii736. 7 indexed citations

Uyterlinde, Wilma, Chun Chen, J. Belderbos, et al.. (2016). Fractures of thoracic vertebrae in patients with locally advanced non-small cell lung carcinoma treated with intensity modulated radiotherapy. Radiotherapy and Oncology. 118(3). 437–441. 8 indexed citations

Uyterlinde, Wilma. (2016). Overcoming toxicity-challenges in chemoradiation for non-small cell lung cancer. Translational Lung Cancer Research. 5(3). 239–243. 2 indexed citations

Hendriks, Lizza, Wilma Uyterlinde, Robin Wijsman, et al.. (2016). Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter?. Lung Cancer. 101. 68–75. 7 indexed citations

Walraven, Iris, Michel M. van den Heuvel, Judi van Diessen, et al.. (2016). Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximab. Radiotherapy and Oncology. 118(3). 442–446. 54 indexed citations

Oberije, Cary, Dirk De Ruysscher, Ruud Houben, et al.. (2015). A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients. International Journal of Radiation Oncology*Biology*Physics. 92(4). 935–944. 76 indexed citations

10.

Molassiotis, Alex, et al.. (2014). Supportive Care in Lung Cancer: Milestones Over the Past 40 Years. Journal of Thoracic Oncology. 10(1). 10–18. 26 indexed citations

11.

Uyterlinde, Wilma, Chun Chen, Jasper Nijkamp, et al.. (2014). Treatment adherence in concurrent chemoradiation in patients with locally advanced non-small cell lung carcinoma: Results of daily intravenous prehydration. Radiotherapy and Oncology. 110(3). 488–492. 9 indexed citations

12.

Uyterlinde, Wilma, Chun Chen, Margriet Kwint, et al.. (2013). Prognostic parameters for acute esophagus toxicity in Intensity Modulated Radiotherapy and concurrent chemotherapy for locally advanced non-small cell lung cancer. Radiotherapy and Oncology. 107(3). 392–397. 31 indexed citations

13.

Uyterlinde, Wilma, J. Belderbos, Erik van Werkhoven, et al.. (2013). Prediction of Acute Toxicity Grade ≥ 3 in Patients With Locally Advanced Non–Small-Cell Lung Cancer Receiving Intensity Modulated Radiotherapy and Concurrent Low-Dose Cisplatin. Clinical Lung Cancer. 14(5). 541–548. 23 indexed citations

14.

Heuvel, Michel M. van den, Wilma Uyterlinde, Andrew Vincent, et al.. (2013). Additional weekly Cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: Efficacy and safety outcomes of a randomized, multi-center phase II study investigating. Radiotherapy and Oncology. 110(1). 126–131. 40 indexed citations

15.

Uyterlinde, Wilma, et al.. (2012). Solitary Bone Metastasis Appearing outside the Usual Range of FDG PET/CT in Stage III Lung Cancer: Is Total Body FDG PET/CT Imaging Mandatory?. Journal of Nuclear Medicine & Radiation Therapy. 3(4). 1 indexed citations

16.

Kwint, Margriet, Wilma Uyterlinde, Jasper Nijkamp, et al.. (2012). Acute Esophagus Toxicity in Lung Cancer Patients After Intensity Modulated Radiation Therapy and Concurrent Chemotherapy. International Journal of Radiation Oncology*Biology*Physics. 84(2). e223–e228. 54 indexed citations

17.

Nijkamp, Jasper, Maddalena Rossi, Joos V. Lebesque, et al.. (2012). Relating acute esophagitis to radiotherapy dose using FDG-PET in concurrent chemo-radiotherapy for locally advanced non-small cell lung cancer. Radiotherapy and Oncology. 106(1). 118–123. 36 indexed citations

18.

Heuvel, Michel M. van den, Andrew Vincent, Wilma Uyterlinde, et al.. (2012). A randomized, multicenter phase II study investigating additional weekly cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: Reporting on the efficacy.. Journal of Clinical Oncology. 30(15_suppl). 7019–7019. 5 indexed citations

19.

Uyterlinde, Wilma, et al.. (2012). Prognostic Model for Progression Free Survival in Patients with Locally Advanced Non-Small Cell Lung Cancer Treated with Concurrent Chemoradiation. Annals of Oncology. 23. ix392–ix393. 1 indexed citations

20.

Zandwijk, Nico van, Tjeerd S. Aukema, J. Belderbos, et al.. (2011). Cetuximab in combination with single agent daily cisplatin chemotherapy concurrent with radiotherapy in locally advanced nonsmall cell lung carcinoma: A feasibility study. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact